Published in Breast Cancer Res Treat on February 07, 2008
In utero supplementation with methyl donors enhances allergic airway disease in mice. J Clin Invest (2008) 3.35
Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch (2010) 1.34
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res (2008) 1.05
RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α. Oncogene (2011) 1.04
Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer (2010) 0.99
Tumor suppressor function of RUNX3 in breast cancer. J Cell Biochem (2012) 0.98
The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer (2009) 0.96
Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer. Oncogene (2012) 0.93
Oncogene-induced senescence: an essential role for Runx. Cell Cycle (2008) 0.92
Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation. BMC Cancer (2015) 0.90
Epigenetic Signatures in Breast Cancer: Clinical Perspective. Breast Care (Basel) (2010) 0.86
The influence of genetic ancestry and ethnicity on breast cancer survival associated with genetic variation in the TGF-β-signaling pathway: The Breast Cancer Health Disparities Study. Cancer Causes Control (2013) 0.86
RUNX3 gene promoter demethylation by 5-Aza-CdR induces apoptosis in breast cancer MCF-7 cell line. Onco Targets Ther (2013) 0.86
Whole genome DNA methylation signature of HER2-positive breast cancer. Epigenetics (2014) 0.83
RUNX3 is a prognostic marker and potential therapeutic target in human breast cancer. J Cancer Res Clin Oncol (2013) 0.81
DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Res (2013) 0.81
Epigenetic targeting in breast cancer: therapeutic impact and future direction. Drug News Perspect (2009) 0.80
Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics. PLoS One (2013) 0.79
Clinicopathological significance and potential drug target of RUNX3 in breast cancer. Drug Des Devel Ther (2014) 0.78
Evaluating genome-wide DNA methylation changes in mice by Methylation Specific Digital Karyotyping. BMC Genomics (2008) 0.78
Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis. J Thorac Dis (2014) 0.78
Epigenetic activation of LY6K predicts the presence of metastasis and poor prognosis in breast carcinoma. Oncotarget (2016) 0.76
An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis. Oncotarget (2016) 0.75
Multiple susceptibility loci for radiation-induced mammary tumorigenesis in F2[Dahl S x R]-intercross rats. PLoS One (2013) 0.75
The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a meta-analysis. Onco Targets Ther (2016) 0.75
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med (2013) 7.48
Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell (2002) 5.69
Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell (2002) 5.07
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res (2010) 4.06
Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood (2002) 3.97
Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth through induction of Indian hedgehog. Genes Dev (2004) 3.33
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J (2005) 3.23
MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev (2010) 2.70
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res (2008) 2.56
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut (2012) 2.36
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat Neurosci (2002) 2.25
Mutations in sodium-borate cotransporter SLC4A11 cause recessive congenital hereditary endothelial dystrophy (CHED2). Nat Genet (2006) 2.20
Integrative analysis of RUNX1 downstream pathways and target genes. BMC Genomics (2008) 2.14
Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J (2004) 2.12
Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs. Stem Cells (2006) 2.11
Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet (2009) 1.96
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem (2008) 1.92
Exome sequencing: dual role as a discovery and diagnostic tool. Ann Neurol (2012) 1.89
Function of the SIRT1 protein deacetylase in cancer. Biotechnol J (2007) 1.88
Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol (2003) 1.88
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol (2008) 1.87
Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther (2006) 1.84
Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol (2011) 1.81
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn (2009) 1.76
RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res (2005) 1.71
Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol (2005) 1.70
Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. Eur Urol (2012) 1.69
Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res (2011) 1.67
JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res (2012) 1.67
Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J Natl Cancer Inst (2014) 1.66
Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer (2008) 1.65
Functional analysis of RUNX2 mutations in Japanese patients with cleidocranial dysplasia demonstrates novel genotype-phenotype correlations. Am J Hum Genet (2002) 1.64
RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol (2005) 1.64
GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat. Free Radic Biol Med (2009) 1.63
A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther (2006) 1.61
The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol (2006) 1.60
RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res (2006) 1.60
MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer (2010) 1.57
Deep whole-genome sequencing of 100 southeast Asian Malays. Am J Hum Genet (2013) 1.55
The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res (2004) 1.54
RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell (2008) 1.54
A systems approach reveals that the myogenesis genome network is regulated by the transcriptional repressor RP58. Dev Cell (2009) 1.53
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A (2002) 1.51
Transcription factor Mohawk and the pathogenesis of human anterior cruciate ligament degradation. Arthritis Rheum (2013) 1.50
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer. Cancer Biol Ther (2011) 1.45
Molecular pathology in contemporary diagnostic pathology laboratory: an opinion for the active role of surgical pathologists. Am J Surg Pathol (2010) 1.43
MAML1 enhances the transcriptional activity of Runx2 and plays a role in bone development. PLoS Genet (2013) 1.42
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut (2012) 1.42
RUNX family: Regulation and diversification of roles through interacting proteins. Int J Cancer (2012) 1.41
Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun (2004) 1.41
Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol (2006) 1.39
Deployment of self-expandable stents for complex proximal superficial femoral artery lesions involving the femoral bifurcation with or without jailed deep femoral artery. Catheter Cardiovasc Interv (2012) 1.39
Mutations in UVSSA cause UV-sensitive syndrome and impair RNA polymerase IIo processing in transcription-coupled nucleotide-excision repair. Nat Genet (2012) 1.38
Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. Hum Mol Genet (2013) 1.38
Usefulness of fractional flow reserve guidance for PCI in acute myocardial infarction. J Invasive Cardiol (2002) 1.38
Measuring Procedure and Maximal Hyperemia in the Assessment of Fractional Flow Reserve for Superficial Femoral Artery Disease. J Atheroscler Thromb (2015) 1.38
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Nomenclature for Runt-related (RUNX) proteins. Oncogene (2004) 1.34
Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biol (2012) 1.33
RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res (2005) 1.32
Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer (2010) 1.32
Helicobacter pylori gamma-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease. Gastroenterology (2010) 1.31
Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta (2009) 1.31
Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res (2011) 1.30
Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol (2003) 1.30
CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol (2010) 1.29
Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One (2013) 1.29